Keep an eye on 11,064 and 11,225 levels as a break on either side would open up for a directional move.  Stocks in news: Alkem Laboratories, Vivimed Labs, Wipro, Bharti Airtel.

Indian markets are expected to the begin the session with modest gains, due to sombre cues from the Asian peers. However, how markets will end today’s session would chiefly depend on the outcome of Reserve Bank of India’s (RBI) policy meet. As the retail inflation is well above the RBI’s comfort zone, street strongly believes that there won’t be any further rate cut.

The consolidated net sales reported in Q1FY21 came in at Rs 53.81 crore, which declined by 40.77 per cent YoY from Rs 90.85 crore in Q1FY20. 

The shares of PI Industries were trading in the green on Wednesday and even rallied to hit an all-time high of Rs 1,966 apiece on BSE after the company reported robust numbers for the first quarter of the financial year 2020-21.

Domestic benchmark indices ended the trading day in the negative territory amid a volatile trading session on Wednesday. Sensex closed down marginally by a mere 24.58 points or 0.07 per cent settling at 37,663.33 while Nifty declined by 24.85 points or 0.22 per cent to close at 11,120.10.

The newly-launched drug, which was the need of the hour, would be available in the form of a strip of ten tablets, marketed under the brand name of Covihalt. It will be used to treat patients having a mild to moderate COVID-19 disease.

Global pharmaceutical major, Zydus Cadila announced on Wednesday that its plasmid DNA vaccine to prevent COVID-19, namely ZyCoV-D, was found to be well-tolerated and safe in phase 1 clinical trial.

Pharma major, Lupin Limited had announced on Tuesday that it has received regulatory approval from United States Food and Drug Administration (USFDA) for its Empagliflozin tablets, 10 mg and 25 mg to market a generic version of Jardiance tablets, 10 mg, and 25 mg, of Boehringer Ingelheim Pharmaceuticals.

Most people believe in the phrase, ‘the more the merrier’. However, that might not hold true with mutual funds. Read on to find out why.

The consolidated net sales reported in Q1FY21 came in at Rs 3,639.9 crore, which increased by 4.11 per cent YoY from Rs 3,496.3 crore in Q1FY20.